Zymeworks Inc

105 articles with Zymeworks Inc

• Zymeworks Announces Corporate Update Conference Call

  5/23/2019

  Zymeworks Inc. announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships.

• Zymeworks and GSK Expand 2016 Azymetric™ Bispecific Agreement

  5/16/2019

  Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas.

• 

  BioSpace Global Roundup, May 16

  5/16/2019

  Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.

• Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

  5/14/2019

  Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.

• Zymeworks Reports 2019 First Quarter Financial Results

  5/2/2019

  Today reported financial results for the first quarter ended March 31, 2019.

• Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development

  4/30/2019

  Zymeworks Inc. announced it has expanded its leadership team with the hiring of three new vice presidents to support the Company’s expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and Bruce Hart, Ph.D., Vice President, Regulatory Affairs.

• Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019

  4/23/2019

  Zymeworks Inc. announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place April 30-May 1, 2019 in Toronto, Canada.

• Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers

  4/15/2019

  Zymeworks Inc. announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas.

• Zymeworks Reports 2018 Year-End Financial Results

  3/6/2019

  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, reported financial results for the year ended December 31, 2018.

• Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration

  1/17/2019

  - Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials - Zymeworks to receive milestone payment of US$8.0 million for this second IND submission - Lilly is one of eight pharma partners; INDs by others anticipated - Total value of remaining potential milestones for all Zymeworks’ partnerships exceeds US$7.6 billion

• Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

  1/6/2019

  Zymeworks Inc. today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019.

• Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

  12/8/2018

  ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates (ADCs)

• Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

  11/14/2018

  ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types

• Zymeworks to Present at Upcoming November 2018 Investor Conferences

  11/7/2018

  Zymeworks Inc. today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.

• ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks

  11/6/2018

  ProBioGen AG announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded expectations.

• Zymeworks Reports Financial Results for the Third Quarter of 2018

  11/6/2018

  Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “

• Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium

  10/30/2018

  ​Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers

• Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration

  10/23/2018

  The companies will collaborate on the discovery of novel monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways with applications in dermatology, inflammation, and autoimmunity by leveraging Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms

• Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration.

  10/23/2018

  Zymeworks Inc. and LEO Pharma A/S have entered into a licensing and research collaboration to discover and develop bispecific antibodies.

• Zymeworks to Webcast R&D Briefing on October 11, 2018

  10/4/2018

  Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City.